Valuation: BioRestorative Therapies, Inc.

Market Cap 2.97M 2.62M 2.48M 2.25M 4.21M 285M 4.26M 29.73M 11.46M 145M 11.15M 10.9M 468M P/E 2026 *
-0.24x
P/E 2027 * -0.29x
Enterprise Value 2.97M 2.62M 2.48M 2.25M 4.21M 285M 4.26M 29.73M 11.46M 145M 11.15M 10.9M 468M EV / Sales 2026 *
2.11x
EV / Sales 2027 * 1.28x
Free-Float
90.44%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 28 27/08/2026
Director of Finance/CFO 38 27/08/2026
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 28 12/06/2026
Director/Board Member 37 12/06/2026
Director/Board Member - 13/07/2026
Change 5-day change 1-year change 3-year change Capi.($)
+1.08%+0.25% - - 2.97M
-0.70%-4.28%+52.62%+86.42% 71.53B
+0.09%+1.60%+37.59%+81.84% 60.12B
+4.77%+6.16%+36.77%+26.10% 27.98B
-1.73%-4.30%-18.37%+357.94% 25.25B
-0.51%-2.28%+0.48%-9.27% 24.76B
+0.58%+1.70%+20.93%-4.62% 20.99B
+3.46%+3.02%+158.90%+337.81% 15.54B
+0.48%+0.86%+44.56%+168.42% 14.53B
+2.96%+0.83%-5.25%+519.59% 14.41B
Average +1.05%-0.79%+36.47%+173.80% 30.57B
Weighted average by Cap. +0.54%-1.52%+36.64%+129.87%

Financials

2026 *2027 *
Net sales 1.4M 1.24M 1.17M 1.06M 1.99M 135M 2.01M 14.07M 5.42M 68.84M 5.28M 5.16M 222M 2.31M 2.04M 1.93M 1.75M 3.28M 222M 3.32M 23.16M 8.93M 113M 8.68M 8.49M 365M
Net income -13.52M -11.93M -11.29M -10.24M -19.2M -1.3B -19.39M -135M -52.21M -663M -50.78M -49.68M -2.13B -15.56M -13.73M -12.99M -11.78M -22.09M -1.49B -22.31M -156M -60.06M -762M -58.42M -57.15M -2.45B
Net Debt - -
Logo BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. is engaged in developing therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). It has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. It also operates a commercial biocosmeceutical platform.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-